E
Emma Ito
Researcher at University Health Network
Publications - 23
Citations - 1457
Emma Ito is an academic researcher from University Health Network. The author has contributed to research in topics: microRNA & Nasopharyngeal carcinoma. The author has an hindex of 14, co-authored 21 publications receiving 1343 citations. Previous affiliations of Emma Ito include University of Toronto & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway
Nehad M. Alajez,Michelle Lenarduzzi,Emma Ito,Angela B.Y. Hui,Wei Shi,Jeff Bruce,Shijun Yue,S.H. Huang,Wei Xu,John Waldron,Brian O'Sullivan,Fei-Fei Liu +11 more
TL;DR: An integrative tumor suppressor function for miR-218 in NPC is defined and it is suggested that restoring mi R-218 expression in NPC might be useful for its clinical management.
Journal ArticleDOI
Nasopharyngeal carcinoma: the next challenges.
Albiruni Ryan Abdul Razak,Lillian L. Siu,Fei-Fei Liu,Emma Ito,Brian O'Sullivan,Kelvin K. W. Chan +5 more
TL;DR: The specific challenges in pushing the boundaries of NPC treatments further are discussed, with an emphasis on prognostic/predictive markers, molecularly targeted therapies, immunotherapies and the areas of interest with regard to long-term toxicities arising from therapeutic interventions.
Journal ArticleDOI
Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98
Nehad M. Alajez,W. Shi,W. Shi,Angela Hui,Angela Hui,Jeff Bruce,Jeff Bruce,Michelle Lenarduzzi,Michelle Lenarduzzi,Emma Ito,Emma Ito,S Yue,Brian O'Sullivan,Brian O'Sullivan,F.F. Liu +14 more
TL;DR: EZH2 is reported as being associated with a higher risk of relapse in NPC patients (P=0.002), and miR-98 was underexpressed in relapsed patient samples, strongly suggesting an important role for the miR -98 and EZh2 axis in NPC biology.
Journal ArticleDOI
Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer.
Wei Shi,Nehad M. Alajez,Nehad M. Alajez,Carlo Bastianutto,Carlo Bastianutto,Angela B.Y. Hui,Angela B.Y. Hui,Joseph D. Mocanu,Joseph D. Mocanu,Emma Ito,Emma Ito,Philippe Busson,Kwok Wai Lo,Raymond H. W. Ng,John Waldron,John Waldron,Brian O'Sullivan,Brian O'Sullivan,Fei-Fei Liu +18 more
TL;DR: The data demonstrate for the first time that underexpressed miR‐100 leads to Plk1 overexpression, which in turn contributes to NPC progression, underscoring the important therapeutic opportunity of PlK1 in NPC.
Journal ArticleDOI
Nasopharyngeal Cancer: Molecular Landscape
TL;DR: An overview of the molecular aberrations that likely drive nasopharyngeal tumor development and progression is provided and the role of genetic and epigenetic variations affecting the human genome in NPC is reviewed.